Longeveron (LGVN) Return on Capital Employed (2023 - 2026)
Longeveron's (LGVN) quarterly Return on Capital Employed came in at 200.88% in Q1 2026, down 11488.0% year-on-year from N/an in Q1 2025, and up 23.9% quarter-over-quarter from 263.97% in Q4 2025.
Longeveron (LGVN) Return on Capital Employed (2023 - 2026) Analysis & Trends
Longeveron's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 200.88% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 11488.0% year-over-year to 200.88% in Q1 2026; TTM through Mar 2026 was 200.88%, a 11488.0% decrease from a year earlier, with the FY2025 full-year figure at 168.47%, down 6671.0% from the prior year.
- Return on Capital Employed improved to 200.88% in Q1 2026 per LGVN's latest filing, from 263.97% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 65.68% in Q4 2024 and bottomed at 364.83% in Q1 2024.
- The 4-year median for Return on Capital Employed is 160.49% (2024), against an average of 171.48%.
- Across the five-year window, Return on Capital Employed slumped 27268 bps in 2024 and soared 27883 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 264.1% in 2023, then surged by 75 bps to 65.68% in 2024, then plunged by 302 bps to 263.97% in 2025, then advanced by 24 bps to 200.88% in 2026.
- Per Business Quant, the three latest LGVN Return on Capital Employed figures stand at 200.88% (Q1 2026), 263.97% (Q4 2025), and 197.71% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | -200.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -200.88% |
| Dec 31, 2025 | -263.97% |
| Sep 30, 2025 | -197.71% |
| Jun 30, 2025 | -125.74% |
| Mar 31, 2025 | -86.00% |
| Dec 31, 2024 | -65.68% |
| Sep 30, 2024 | -82.03% |
| Jun 30, 2024 | -160.49% |
| Mar 31, 2024 | -364.83% |
| Dec 31, 2023 | -264.10% |
| Sep 30, 2023 | -189.97% |
| Jun 30, 2023 | -135.71% |
| Mar 31, 2023 | -92.15% |